VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program
Partnership Announcement: VERAXA Biotech AG has formed a co-discovery alliance with OmniAb, Inc. to develop a novel bispecific antibody drug conjugate (bsADC) program targeting solid tumors, combining their respective technologies for enhanced cancer therapy development.
Business Combination Plans: VERAXA is set to become publicly traded through a business combination with Voyager Acquisition Corp., aiming to leverage strategic partnerships and innovative technologies in the healthcare sector to drive growth and deliver new therapeutic solutions.
Trade with 70% Backtested Accuracy
Analyst Views on VACHU
No data
About the author
VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program
Partnership Announcement: VERAXA Biotech AG has formed a co-discovery alliance with OmniAb, Inc. to develop a novel bispecific antibody drug conjugate (bsADC) program targeting solid tumors, combining their respective technologies for enhanced cancer therapy development.
Business Combination Plans: VERAXA is set to become publicly traded through a business combination with Voyager Acquisition Corp., aiming to leverage strategic partnerships and innovative technologies in the healthcare sector to drive growth and deliver new therapeutic solutions.
VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies
VERAXA's Business Combination: VERAXA Biotech AG is set to merge with Voyager Acquisition Corp., creating a publicly traded biopharmaceutical company focused on next-generation cancer therapies, with an estimated pre-money equity value of $1.3 billion and plans for NASDAQ listing under the ticker "VERX" by Q4 2025.
Innovative Cancer Therapies: The company is advancing its proprietary BiTAC platform to develop novel antibody-drug conjugates (ADCs) and bispecific T-cell engagers (TCEs), targeting significant growth markets in cancer therapy, with a robust pipeline including nine programs currently in various stages of development.
VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination to Advance Next-Generation Cancer Therapies
Business Combination Announcement: VERAXA Biotech AG is merging with Voyager Acquisition Corp. to form a publicly traded clinical-stage biopharmaceutical company focused on innovative cancer therapies, valued at approximately $1.3 billion, with the merger expected to close in Q4 2025.
Pipeline and Technology Focus: The company aims to leverage its proprietary BiTAC technology platform to develop next-generation cancer treatments, including antibody-drug conjugates and bispecific T-cell engagers, while actively pursuing partnerships to enhance its development programs.
Voyager Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing on or about September 30, 2024
Unit Trading Announcement: Voyager Acquisition Corp. announced that holders of its initial public offering units can begin separately trading Class A ordinary shares and warrants starting September 30, 2024, with specific trading symbols assigned for each component.
Company Overview: The company is a blank check entity seeking to engage in business combinations and has made forward-looking statements regarding its search for an initial business combination, subject to various risks outlined in its SEC registration statement.
Voyager Acquisition Corp. Announces Closing of $253,000,000 Initial Public Offering
Initial Public Offering Details: Voyager Acquisition Corp. successfully closed its IPO, raising $253 million by offering 25.3 million units at $10 each, with trading commencing on Nasdaq under the ticker "VACHU".
Company Overview and Future Plans: As a blank check company based in the Cayman Islands, Voyager aims to pursue business combinations through mergers or acquisitions, with future trading expected for its Class A shares and warrants under separate symbols.
Voyager Acquisition Corp. Announces Pricing of $220,000,000 Initial Public Offering
Initial Public Offering Announcement: Voyager Acquisition Corp. has priced its initial public offering at $10.00 per unit, consisting of 22 million units, which will begin trading on Nasdaq under the ticker "VACHU" starting August 9, 2024, with an expected closing date of August 12, 2024.
Company Overview and Future Plans: The company is a blank check entity aiming to pursue business combinations through mergers or acquisitions, with Cantor Fitzgerald & Co. as the lead manager for the offering.
VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program
Partnership Announcement: VERAXA Biotech AG has formed a co-discovery alliance with OmniAb, Inc. to develop a novel bispecific antibody drug conjugate (bsADC) program targeting solid tumors, combining their respective technologies for enhanced cancer therapy development.
Business Combination Plans: VERAXA is set to become publicly traded through a business combination with Voyager Acquisition Corp., aiming to leverage strategic partnerships and innovative technologies in the healthcare sector to drive growth and deliver new therapeutic solutions.
VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies
VERAXA's Business Combination: VERAXA Biotech AG is set to merge with Voyager Acquisition Corp., creating a publicly traded biopharmaceutical company focused on next-generation cancer therapies, with an estimated pre-money equity value of $1.3 billion and plans for NASDAQ listing under the ticker "VERX" by Q4 2025.
Innovative Cancer Therapies: The company is advancing its proprietary BiTAC platform to develop novel antibody-drug conjugates (ADCs) and bispecific T-cell engagers (TCEs), targeting significant growth markets in cancer therapy, with a robust pipeline including nine programs currently in various stages of development.
VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination to Advance Next-Generation Cancer Therapies
Business Combination Announcement: VERAXA Biotech AG is merging with Voyager Acquisition Corp. to form a publicly traded clinical-stage biopharmaceutical company focused on innovative cancer therapies, valued at approximately $1.3 billion, with the merger expected to close in Q4 2025.
Pipeline and Technology Focus: The company aims to leverage its proprietary BiTAC technology platform to develop next-generation cancer treatments, including antibody-drug conjugates and bispecific T-cell engagers, while actively pursuing partnerships to enhance its development programs.
Voyager Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing on or about September 30, 2024
Unit Trading Announcement: Voyager Acquisition Corp. announced that holders of its initial public offering units can begin separately trading Class A ordinary shares and warrants starting September 30, 2024, with specific trading symbols assigned for each component.
Company Overview: The company is a blank check entity seeking to engage in business combinations and has made forward-looking statements regarding its search for an initial business combination, subject to various risks outlined in its SEC registration statement.
Voyager Acquisition Corp. Announces Closing of $253,000,000 Initial Public Offering
Initial Public Offering Details: Voyager Acquisition Corp. successfully closed its IPO, raising $253 million by offering 25.3 million units at $10 each, with trading commencing on Nasdaq under the ticker "VACHU".
Company Overview and Future Plans: As a blank check company based in the Cayman Islands, Voyager aims to pursue business combinations through mergers or acquisitions, with future trading expected for its Class A shares and warrants under separate symbols.
Voyager Acquisition Corp. Announces Pricing of $220,000,000 Initial Public Offering
Initial Public Offering Announcement: Voyager Acquisition Corp. has priced its initial public offering at $10.00 per unit, consisting of 22 million units, which will begin trading on Nasdaq under the ticker "VACHU" starting August 9, 2024, with an expected closing date of August 12, 2024.
Company Overview and Future Plans: The company is a blank check entity aiming to pursue business combinations through mergers or acquisitions, with Cantor Fitzgerald & Co. as the lead manager for the offering.
